Fresh analysis reveals that people who come off new GLP-1 drugs like Wegovy and Mounjaro can put back on shed pounds far faster than those who halt traditional diet and exercise regimens.
Published data in a major health publication demonstrates that while obese individuals often shed substantial amounts of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.
"People purchasing these treatments should be aware of the danger of fast weight regain when the therapy is stopped," stated researcher Dr. Susan Jebb.
That rate of recovery implies a return to pre-treatment mass in about one and a half years.
Analyzing Treatments
The research, which examined 37 of studies involving thousands of participants, compared the outcomes of the injectable medications with conventional dieting.
The team emphasize that individuals who shed pounds through dieting generally see a less rapid creep back—perhaps 100 grams monthly—after stopping.
Explaining the Fast Rebound
Nutrition scientists believe the mode of action of the drugs is key to understanding the amplified regain.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls appetite.
"Artificially providing GLP-1 levels far above than the body's typical production could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition specialist.
"Withdrawal of this hormone supplement means hunger is uncontrolled, making excessive eating a significant risk."
A Lifelong Condition?
The NHS suggest the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
Many experts argue that, given the likelihood of weight regain, the therapy might need to be ongoing.
This perspective is supported by drug manufacturers, who say that the results "highlight the long-term character of obesity," akin to managing conditions like diabetes.
User Experiences
Users who have come off the jabs report a sudden resurgence of cravings.
"I experienced a trigger that goes on and you become starving," said an individual.
The struggle is exacerbated if patients have not developed lasting dietary or behavioural modifications during treatment.
Growing Adoption
Survey data suggest that millions of adults in the UK have tried these injections in the past year, with demand remaining high.
- Use is higher among females than men.
- The middle-aged age group shows the greatest level of interest.
- Many access the drugs through private prescriptions rather than public health services.
Ultimately, experts emphasize that while the jabs are powerful agents for weight loss, they are not a standalone fix and maintained weight loss hinges on combined behavioural support.
